Polypharmacy with second-generation antipsychotics: A review of evidence

Journal of Psychiatric Practice

Volumn 14, Issue 6, 2008, Pages 345-367

  Pandurangi, Anand K ^a   Dalkilic, Alican ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Combination treatment; Partial responders; Polypharmacy; Schizophrenia; Second generation (atypical) antipsychotic; Treatment refractory psychosis

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLONAZEPAM; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUCONAZOLE; FLUOXETINE; HALOPERIDOL; OLANZAPINE; PAROXETINE; PRAMIPEXOLE; PROPRANOLOL DERIVATIVE; QUETIAPINE; RISPERIDONE; ROPINIROLE; SERTRALINE; SULPIRIDE; THIORIDAZINE; ZIPRASIDONE; NEUROLEPTIC AGENT;

AGGRESSION; AGITATION; AGRANULOCYTOSIS; AKATHISIA; ALGORITHM; ANXIETY; AUDITORY HALLUCINATION; AUTOMUTILATION; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; COMPULSION; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DROWSINESS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRASYSTOLE; FATIGUE; FIBROMA; HALLUCINATION; HEART ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; INSOMNIA; LEUKOPENIA; MONOTHERAPY; MOOD; MORNING DOSAGE; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; OCULOGYRIC CRISIS; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARANOIA; POLYPHARMACY; POPULATION; PRESCRIPTION; PREVALENCE; PRIAPISM; PROLACTIN BLOOD LEVEL; PSYCHOMOTOR DEVELOPMENT; PSYCHOSIS; QT INTERVAL; QT PROLONGATION; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SUPRAVENTRICULAR PREMATURE BEAT; TARDIVE DYSKINESIA; THERAPY EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA; DRUG COMBINATION;

ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; POLYPHARMACY; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 65849514380     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000341890.05383.45     Document Type: Review

References (153)

1. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
2. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
3. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60:553-64.
4. Kapur S, Remington G. Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001;52:503-17.
5. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: Comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 2004;11:313-27.
6. Physicians' Desk Reference 2008. PDR. Williston, VT: Thomson Medical; 2007.
7. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-62.
8. Lerner V. High-dose olanzapine for treatment-refractory schizophrenia. Clin Neuropharmacol 2003;26:58-61.
9. Tollefson GD, Birkett MA, Kiesler GM, et al. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 2001;49:52-63.
10. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose doubleblind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997;54:549-57.
11. Crossman AM, Lindenmayer JP.Tolerability of high-dose aripiprazole in treatment refractory schizophrenic patients. J Clin Psychiatry 2006;67:1158-9.
12. Duggal HS, Mendhekar DN. High-dose aripiprazole in treatment-resistant schizophrenia. J Clin Psychiatry 2006;67: 674-5.
13. Meltzer HY, Bobo WV, Roy A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2008;69:274-85.
14. Casey DE, Daniel DG, Wassef AA, et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003;28:182-92.
15. Megna JL, Devitt PJ, Sauro MD, et al. Gabapentin's effect on agitation in severely and persistently mentally ill patients. Ann Pharmacother 2002;36:12-6.
16. Martin JC, Palenciano G, Perez R. The effectiveness of combining lithium with olanzapine in the treatment of resistant schizophrenia. J Clin Psychiatry 2000;61:948.
17. Kremer I, Vass A, Gorelik I, et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry 2004;56:441-6.
18. Tiihonen J, Hallikainen T, Ryynanen OP, et al. Lamotrigine in treatment-resistant schizophrenia: A randomized placebocontrolled crossover trial. Biol Psychiatry 2003;54:1241-8.
19. Tiihonen J, Halonen P, Wahlbeck K, et al. Topiramate add-on in treatment-resistant schizophrenia: A randomized, double blind, placebo-controlled, crossover trial. J Clin Psychiatry 2005;66:1012-5.
20. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: A review and reappraisal. Am J Psychiatry 1991;148:714-26.
21. Hollister LE, Muller-Oerlinghausen B, Rickels K, et al. Clinical uses of benzodiazepines. J Clin Psychopharmacol 1993;13:1S-169S.
22. Chanpattana W. Maintenance ECT in treatment-resistant schizophrenia. J Med Assoc Thai 2000;83:657-62.
23. Chanpattana W, Andrade C. ECT for treatment-resistant schizophrenia: A response from the far East to the UK. NICE report. J ECT 2006;22:4-12.
24. Kupchik M, Spivak B, Mester R, et al. Combined electroconvulsive- clozapine therapy. Clin Neuropharmacol 2000;23:14-6.
25. Tang WK, Ungvari GS. Efficacy of electroconvulsive therapy in treatment-resistant schizophrenia: A prospective open trial. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:373-9.
26. Tang WK, Ungvari GS. Efficacy of electroconvulsive therapy combined with antipsychotic medication in treatment-resistant schizophrenia: A prospective, open trial. J ECT 2002;18:90-4.
27. Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004;65:1377-88.
28. Faries D, Ascher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005;5:26.
29. Megna JL, Kunwar AR, Mahlotra K, et al. A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness. J Psychiatr Pract 2007;13:129-37.
30. Botts S, Hines H, Littrell R. Antipsychotic polypharmacy in the ambulatory care setting, 1993-2000. Psychiatr Serv 2003;54:1086.
31. Lerner V, Chudakova B, Kravets S, et al. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: A preliminary case series report. Clin Neuropharmacol 2000;23:284-6.
32. Florez Menéndez G, Blanco Ramos M, Gómez-Reino Rodríguez I, et al. Polypharmacy in the antipsychotic prescribing practices in a psychiatric out-patient clinic [Spanish]. Actas Esp Psiquiatr 2004;32:333-9.
33. Sernyak MJ, Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. J Clin Psychiatry 2004;65:1597-600.
34. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacol Bull 1988;24:97-9.
35. Guy W. ECDEU assessment manual for psychopharmacology-revised (DHEW Publ. No ADM 76-338). Rockville, MD: U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs 1976:218-22.
36. Eisen C, Shaner R, Unutzer J, et al. Second-generation antipsychotic medication combinations for schizophrenia. Psychiatr Serv 2008;59:235.
37. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:1-56.
38. Moore TA, Buchanan RW, Buckley PF, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007;68: 1751-62.
39. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double blind, placebo-controlled study. Br J Psychiatry 1997;171:569-73.
40. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: A randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005;162:130-6.
41. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, et al. A double blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: Efficacy and safety. J Clin Psychiatry 2005;66:63-72.
42. Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;354:472-82.
43. Freudenreich O, Henderson DC, Walsh JP, et al. Risperidone augmentation for schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled trial. Schizophr Res 2007;92:90-4.
44. Kotler M, Strous RD, Reznik I, et al. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: Evidence for improvement of mood symptomatology. Int Clin Psychopharmacol 2004;19:23-6.
45. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 2000;25:161-6.
46. Nordstrom AL, Farde L,Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-35.
47. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia: A review of efficacy and risk of current combinations. Acta Psychiatr Scand 2002;106:323.
48. Kapur S, Zipursky RB, Remington G, et al. 5HT-2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation. Am J Psychiatry 998;155:921-8.
49. Baca E, Azanza JR, Giner J, et al. Ziprasidone: From pharmacology to the clinical practice. One year of experience. Actas Esp Psiquiatr 2005;33:311-24.
50. Nemeroff CB, Lieberman JA, Weiden PJ, et al. From clinical research to clinical practice: A 4-year review of ziprasidone. CNS Spectr 2005;10:s1-20.
51. Sharif Z. Dr. Sharif Replies. Prim Care Companion J Clin Psychiatry 2003;5:236.
52. Tyson SC, Devane CL, Risch SC. Pharmacokinetic interaction between risperidone and clozapine. Am J Psychiatry 1995;152:1401-2.
53. Koreen AR, Lieberman JA, Kronig M, et al. Cross-tapering clozapine and risperidone. Am J Psychiatry 1995;152:1690.
54. Raaska K, Raitasuo V, Neuvonen PJ. Therapeutic drug monitoring data: Risperidone does not increase serum clozapine concentration. Eur J Clin Pharmacol 2002;58:587-91.
55. Henderson DC, Kunkel L, Nguyen DD, et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006;113:142-7.
56. Ziegenbein M, Calliess IT. Clozapine and ziprasidone: A useful combination in patients with treatment-resistant schizophrenia. J Neuropsychiatry Clin Neurosci 2006;18:246-7.
57. Ziegenbein M, Kropp S, Kuenzel HE. Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: An open clinical study. Clin Neuropharmacol 2005;28:220-4.
58. Ziegenbein M, Sieberer M, Calliess IT, and et al. Combination of clozapine and aripiprazole: A promising approach in treatment-resistant schizophrenia. Aust N Z J Psychiatry 2005;39:840-1.
59. Stahl SM. Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret? J Clin Psychiatry 1999;60:425-6.
60. Preskorn SH, Lacey RL. Polypharmacy: When is it rational? J Psychiatr Pract 2007:2:97-105.
61. Bitter I, Czobor P, Dossenbach M, et al. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and violent behavior in outpatients with schizophrenia. A prospective naturalistic study (IC-SOHO). Eur Psychiatry 2005;20:403-8.
62. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91.
63. Hamann J, Leucht S, Kissling W. Are the second-generation antipsychotics cost effective? A critical review on the background of different health systems. Pharmacopsychiatry 2003;36:18-26.
64. Bounthavong M, Okamoto MP. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. J Eval Clin Pract 2007;13:453-60.
65. Rosenheck RA, Leslie DL, Sindelar J, et al., CATIE Study Investigators. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006;163:2080-9.
66. Rosenheck RA, Lieberman JA. Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia. J Clin Psychiatry 2007;68:e05.
67. Davies LM, Lewis S, Jones PB, et al., CUTLASS team. Costeffectiveness of first- v. second-generation antipsychotic drugs: Results from a randomized controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry 2007;191:14-22.
68. Tempier RP, Pawliuk NH. Conventional, atypical, and combination antipsychotic prescriptions: A 2-year comparison. J Clin Psychiatry 2003;64673-9.
69. Reinstein MJ, Sirotovskaya LA, Jones LE, et al. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control: Preliminary findings. Clin Drug Investig 1999;18:99-104.
70. Kaye NS. Ziprasidone augmentation of clozapine in 11 patients. J Clin Psychiatry 2003;64:215-6.
71. Lerner V, Libov I, Kotler M, et al. Combination of "atypical" antipsychotic medication in the management of treatmentresistant schizophrenia and schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:89-98.
72. Patrick V, Levin E, Schleifer S. Antipsychotic polypharmacy: Is there evidence for its use? J Psychiatr Pract 2005;11:248-57.
73. Chan J, Sweeting M. Combination therapy with non-clozapine atypical antipsychotic medication: A review of current evidence. J Psychopharmacol 2007;21:657-64.
74. DeQuardo JR. Increased efficacy with addition of clozapine to aripiprazole: Alternative explanations. J Clin Psychiatry 2005;66:396; author reply 396.
75. Ramaswamy S, Vijay D, William M, et al. Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol 2004;19:45-8.
76. Reeves RR, Mack JE.Worsening schizoaffective disorder with aripiprazole. Am J Psychiatry 2004;161:1308.
77. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996;57:395-7.
78. Taylor CG, Flynn SW, Altman S, et al. An open trial of risperidone augmentation of partial response to clozapine. Schizophr Res 2001;48:155-8.
79. de Groot IW, Heck AH, van Harten PN. Addition of risperidone to clozapine therapy in chronically psychotic inpatients. J Clin Psychiatry 2001;62:129-30.
80. Henderson DC, Goff DC, Connolly CE, et al. Risperidone added to clozapine: Impact on serum prolactin levels. J Clin Psychiatry 2001;62:605-8.
81. Procyshyn RM, Tse G, Sin O, et al. Concomitant clozapine reduces smoking in patients treated with risperidone. Eur Neuropsychopharmacol 2002;12:77-80.
82. Zervas IM, Kattan K, Mantonakis I. Risperidone-clozapine combination for refractory schizophrenia. Eur Neuropsychopharmacol 1998;8:S37.
83. Mantonakis I, Kattan K, Zervas IM. Risperidone augmentation of clozapine and olanzapine for refractory schizophrenia. Eur Neuropsychopharmacol 1998;8:233.
84. Raskin S, Katz G, Zislin Z, et al. Clozapine and risperidone: Combination/augmentation treatment of refractory schizophrenia: A preliminary observation. Acta Psychiatr Scand 2000;101:334-6.
85. McCarthy RH, Terkelsen KG. Risperidone augmentation of clozapine. Pharmacopsychiatry 1995;28:61-3.
86. Morera AL, Barreiro P, Cano-Munoz JL. Risperidone and clozapine combination for the treatment of refractory schizophrenia. Acta Psychiatr Scand 1999;99:305-6; discussion 306-7.
87. Adesanya A, Pantelis C. Adjunctive risperidone treatment in patients with 'clozapine resistant schizophrenia'. Aust N Z J Psychiatry 2000;34:533-4.
88. Raju, Kumar R, Khanna S. Clozapine-risperidone combination in treatment-resistant schizophrenia. Aust N Z J Psychiatry 2001;35:543.
89. Chong SA, Tan CH, Lee HS. Hoarding and clozapine-risperidone combination. Can J Psychiatry 1996;41:315-6.
90. Godleski LS, Sernyak MJ. Agranulocytosis after addition of risperidone to clozapine treatment. Am J Psychiatry 1996;153:735-6.
91. Chong SA, Tan CH, Lee HS. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: Two case reports. J Clin Psychopharmacol 1997;17:68-9.
92. Patel JK, Salzman C, Green AI, et al. Chronic schizophrenia: Response to clozapine, risperidone, and paroxetine. Am J Psychiatry 1997;154:543-6.
93. Beauchemin MA, Millaud F, Nguyen KA. A case of neuroleptic malignant syndrome with clozapine and risperidone. Can J Psychiatry 2002;47:886.
94. Kontaxakis VP, Havaki-Kontaxaki BJ, Stamouli SS, et al. Toxic interaction between risperidone and clozapine: A case report. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:407-9.
95. Senechal A, Landry P, Deschamps R, et al. Neutropenia in a patient treated with clozapine in combination with other psychotropic drugs. Encephale 2002;28:567-9.
96. Andreasen N. Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa; 1983.
97. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
98. Akdede BB, Anil Yagcioglu AE, Alptekin K, et al. A doubleblind study of combination of clozapine with risperidone in patients with schizophrenia: Effects on cognition. J Clin Psychiatry 2006;67:1912-9.
99. Genc Y, Taner E, Candansayar S. Comparison of clozapineamisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: A single-blind randomized study. Adv Ther 2007;24:1-13.
100. Shiloh R. Sulpride adjunction to clozapine in treatment resistant schizophrenic patients: A preliminary case series study. Eur Psychiatry 1997;12:152-5.
101. Agelink MW, Kavuk I, Ak I. Clozapine with amisulpride for refractory schizophrenia. Am J Psychiatry 2004;161:924-5.
102. Zink M, Knopf U, Henn FA, et al. Combination of clozapine and amisulpride in treatment-resistant schizophrenia: Case reports and review of the literature. Pharmacopsychiatry 2004;37:26-31.
103. Kämpf P, Agelink MW, Naber D. Augmentation of clozapine with amisulpride: A promising therapeutic approach to refractory schizophrenic symptoms. Pharmacopsychiatry 2005;38:39-40.
104. Lerner V, Bergman J, Borokhov A, et al. Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. Clin Neuropharmacol 2005;28:66-71.
105. Andreasen N. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: University of Iowa; 1984.
106. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987; 334:1-100.
107. Simpson-GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 212:11-19.
108. Gupta S, Sonnenberg SJ, Frank B. Olanzapine augmentation of clozapine. Ann Clin Psychiatry 1998;10:113-5.
109. Rhoads E. Polypharmacy of 2 atypical antipsychotics. J Clin Psychiatry 2000;61:678-80.
110. Diaz P, Hogan TP. Granulocytopenia with clozapine and quetiapine. Am J Psychiatry 2001;158:651.
111. Zink M, Mase E, Dressing H. Combination of ziprasidone and clozapine in treatment-resistant schizophrenia. Hum Psychopharmacol 2004;19:271-3.
112. Zink M, Mase E, Dressing H. Ziprasidone-augmentation of clozapine. Psychiatr Prax 2004;31:259-61.
113. Lim S, Pralea C, Schnitt J, et al. Possible increased efficacy of low dose clozapine when combined with aripiprazole. J Clin Psychiatry 2004;65:1284-5.
114. Clarke LA, Lindenmayer JP, Kaushik S. Clozapine augmentation with aripiprazole for negative symptoms. J Clin Psychiatry 2006;67:675-6.
115. Keller Ashton A. Indexing of reports on aripiprazole augmentation of clozapine. J Clin Psychiatry 2007;68:334-5.
116. Rocha FL, Hara C. Benefits of combining aripiprazole to clozapine: Three case reports. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1167-9.
117. Karunakaran K, Tungaraza TE, Harborne GC. Is clozapinearipiprazole combination a useful regime in the management of treatment-resistant schizophrenia? J Psychopharmacol 2007;21:453-6.
118. Abu-Tair F, Kopitz J, Bergemann N. Clozapine augmented with aripiprazole in 5 patients with schizophrenia. J Clin Psychopharmacol 2006;26:669-71.
119. Mitsonis CI, Dimopoulos NP, Mitropoulos PA, et al. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:373-7.
120. Ashton AK. Aripiprazole augmentation of clozapine in refractory schizophrenia [letter]. Psychiatry 2005 2005;2:18-9.
121. Potkin SG, Thyrum PT, Alva G, et al. The safety and pharmacokinetics of quetiapine when co-administered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol 2002;22:121-30.
122. John V, Rapp M, Pies R. Aggression, agitation, and mania with olanzapine. Can J Psychiatry 1998;43:1054.
123. Seger A, Lamberti JS. Priapism associated with polypharmacy. J Clin Psychiatry 2001;62:128.
124. Bork JA, Rogers T,Wedlund PJ, et al. A pilot study on risperidone metabolism: The role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 1999;60:469-76.
125. Nelson MW, Reynolds RR, Kelly DL, et al. Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone. Clin Neuropharmacol 2003;26:297-8.
126. Guy W. ECDEU assessment manual for psychopharmacology-revised (DHEW Publ. No ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs 1976: 534-7.
127. Chue P, Welch R, Snaterse M. Combination risperidone and quetiapine therapy in refractory schizophrenia. Can J Psychiatry 2001;46:86-7.
128. Beelen AP, Yeo KT, Lewis LD. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum Exp Toxicol 2001; 20:215-9.
129. Bozikas VP, Deseri C, Pitsavas S, et al. Antiaggressive action of combined risperidone and quetiapine in a patient with schizophrenia. Can J Psychiatry 2003;48:426-7.
130. Ichikawa J, Meltzer HY. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci 1999;249:90-8.
131. Volavka J. The neurobiology of violence: An update. J Neuropsychiatry Clin Neurosci 1999;11:307-14.
132. Margolese HC, Kolivakis TT, Turnier L, et al. Clinical improvement with quetiapine augmentation of combination atypical antipsychotic pharmacotherapy in treatment resistant schizophrenia and schizoaffective disorder. Presented at 39th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, Dec. 10-14, 2000:188.
133. Hedges DW, Jeppson KG. New-onset seizure associated with quetiapine and olanzapine. Ann Pharmacother 2002;36:437-9.
134. Dunkley MJ, Reveley MA. Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma. J Psychopharmacol 2005;19:97-101.
135. Duggal HS. Aripiprazole-olanzapine combination for treatment of schizophrenia. Can J Psychiatry 2004;49:151.
136. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
137. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-5.
138. Barnes TRE. A rating scale for drug-induced akathesia. Br J Psychiatry 1989;154:672-6.
139. Zink M, Henn FA, Thome J. Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses. Eur Psychiatry 2004;19:56-8.
140. American Psychiatric Association. Global Assessment of Functioning scale. In: Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC: American Psychiatric Association; 2000: 32-4.
141. Raskin S, Durst R, Katz G, et al. Olanzapine and sulpride: A preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia. J Clin Psychopharmacol 2000;20:500-3.
142. Pedrosa GF, Schneider,C, Grohmann R, et al. Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy. Nervenarzt 2001;72:729-33.
143. Minov C. Risk of QTc prolongation due to combination of ziprasidone and quetiapine. Psychiatr Prax 2004;31:S142-4.
144. Jones GH. 'Clozapine effect' without the blood tests? Prog Neurol Psychiatry 2002;6:32.
145. O'Shea M, Sazhin V, Collins A. Ventricular ectopics during crossover of atypical antipsychotics. Aust N Z J Psychiatry 2003;37:773-4.
146. Stern RG, Schmeidler J. Davidson M. Limitations of controlled augmentation trials in schizophrenia. Biol Psychiatry 1997;42:138-43.
147. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998;173:325-9.
148. Passchier J, Gee A, Willemsen A, et al. Measuring drug-related receptor occupancy with positron emission tomography. Methods 2002;27:278-86.
149. Rush AJ, Fava M,Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design. Control Clin Trials 2004;25:119-42.
150. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: A STAR*D report. Am J Psychiatry 2006;163:1519-30; quiz 1665.
151. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-42.
152. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: A STAR*D report. Am J Psychiatry 2006;163:1531-41; quiz 1666.
153. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: A STAR*D report. Am J Psychiatry 2006;163:1161-72.